China’s drugmakers can’t sell mRNA shots but haven’t quit yet

​CSPC’s first shot faced limited distribution by health authorities, partly because it did not target a more recent variant or had stricter storage and transport requirements than standard technology shots, staff at some medical institutions in China’s two most populous cities, Beijing and Shanghai, told Reuters.
Source – ETHealth World